Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gradual Initiation of SMX/TMP for PCP Prophylaxis
NCT00000816Phase 4Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 4, randomised, double-blind trial of trimethoprim + sulfamethoxazole in Pneumocystis jirovecii pneumonia (PJP) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoint: Incidence of treatment-limiting adverse reactions at 12 weeks. Status: completed.
02
Drugs
trimethoprim + sulfamethoxazole
03
Conditions
Pneumocystis jirovecii pneumonia (PJP)
Beyond the preview
Go deeper on NCT00000816.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00000816.